deal
mucos
deliveri
system
mean
deal
mucu
name
mucosa
come
mucu
dens
fluid
enrich
glycoprotein
mucin
main
function
protect
delic
mucos
epithelium
mucu
provid
barrier
physiolog
chemic
physic
aggressor
ie
host
secret
digest
product
bile
acid
enzym
food
particl
also
potenti
noxiou
microbiota
product
intestin
mucosa
cover
human
host
consequ
major
portal
entri
major
known
pathogen
turn
microorgan
evolv
mani
differ
approach
circumv
barrier
direct
consequ
natur
coevolut
understand
mechan
known
virul
factor
use
interact
andor
disrupt
mucos
barrier
instruct
us
ration
design
nanoparticul
deliveri
system
intend
oral
vaccin
immunotherapi
review
deal
mimet
approach
obtain
nanocarri
capabl
reach
epitheli
cell
oral
deliveri
parallel
induc
strong
longlast
immun
protect
respons
oral
administr
bioactiv
product
ie
drug
antigen
immunomodul
attract
desir
option
divers
point
view
econom
safeti
needlefre
easi
effici
particularli
vaccin
deliveri
take
account
oral
vaccin
induc
system
includ
mucos
immun
respons
howev
practic
face
hard
well
organ
frontier
mucosa
mucu
secret
epithelium
line
intern
part
bodi
intestin
mucosa
made
epithelium
lamina
propria
musculari
mucosa
epithelium
constitut
cell
held
togeth
tight
junction
effect
form
seal
extern
environ
addit
two
extra
level
protect
outer
milieu
secret
mucu
layer
apic
glycocalyx
fig
global
consid
layer
constitut
mucu
cover
tip
microvilli
apic
surfac
intestin
enterocyt
mucu
provid
barrier
physic
chemic
aggressor
food
residu
host
secret
digest
product
eg
bile
acid
enzym
also
potenti
noxiou
microbiota
product
surprisingli
pathogen
evolv
mani
way
evad
mucos
barrier
fact
mucosa
cover
human
host
consequ
major
portal
entri
major
known
pathogen
review
deal
gener
nanocarri
base
microorganismmimick
approach
oral
deliveri
either
antigen
allergen
vaccin
immunotherapi
purpos
mucu
complex
viscou
secret
basic
form
water
approx
salt
lipid
variou
kind
macromolecul
includ
socal
mucin
mucin
secret
goblet
cell
dens
glycosyl
protein
protein
backbon
apomucin
link
number
carbohydr
chain
weight
addit
carbohydr
structur
either
linear
branch
acid
contain
sialic
acid
sulphat
group
neutral
natur
degre
type
glycosyl
differ
depend
type
mucin
local
throughout
gut
glycoprotein
found
oligom
nonoligom
http
elsevi
bv
right
reserv
initi
classifi
three
subfamili
solubl
nm
long
membranebound
nm
gelform
mucin
sever
micrometr
gelform
mucin
major
constitu
mucu
respons
viscoelast
properti
function
point
view
mucu
appear
dens
fluid
matrix
requir
inelud
porou
gel
sinc
need
allow
diffus
molecul
orient
cell
absorpt
nutrient
cell
secret
howev
time
need
provid
effect
physic
barrier
foreign
particul
matter
includ
microorgan
achiev
success
function
mucu
dispos
arrang
compris
two
differ
layer
extern
name
mucu
layer
intern
one
glycocalyx
correspond
glycoprotein
attach
epitheli
cell
surfac
mucu
layer
constitut
first
line
defenc
epithelia
damag
physic
chemic
biolog
aggress
thick
lm
small
intestin
lm
larg
intestin
constantli
renew
host
approx
lday
topograph
compris
two
layer
outer
layer
lm
diamet
loos
attach
larg
function
pore
allow
resid
normal
microbiota
ii
inner
layer
attach
subjac
glycocalyx
therefor
dens
pack
small
function
pore
imped
microbi
particl
penetr
predict
model
physic
mucin
pore
level
around
nm
although
nativ
mucin
fibr
may
aggreg
certain
circumst
creat
larger
pore
allow
larger
particl
transit
glycocalyx
consist
long
filament
divers
glycoprotein
glycolipid
well
attach
cell
surfac
enterocyt
thin
robust
compact
layer
lm
thick
small
intestin
around
lm
larg
intestin
fact
layer
would
abl
detain
macromolecul
nm
glycocalyx
renew
everi
h
releas
lumen
trap
concentr
mucu
layer
addit
epitheli
cell
activ
secret
mucin
block
microorgan
lumen
reach
epitheli
cell
fig
show
schemat
represent
intestin
mucosa
sum
structur
mucin
fibr
contain
hydrophob
domain
altern
hydrophil
glycosid
region
allow
interact
empath
area
adjac
mucin
even
molecul
consequ
mucin
fibr
flexibl
sticki
energi
invest
mucos
tissu
product
mucin
fine
tune
modul
respons
chemic
physic
biolog
challeng
infect
reflect
import
glycoprotein
fact
chang
mucin
glycosyl
consid
mechan
innat
immun
respons
mucos
infect
case
mucu
layer
insurmount
microbi
world
motil
degrad
enzym
main
strategi
use
mani
microbi
pathogen
penetr
mucu
layer
consid
follow
section
harsh
condit
gastrointestin
tract
well
presenc
intens
peristalt
wave
forc
compromis
viabil
surviv
microorgan
within
gut
mani
develop
differ
trick
interact
even
penetr
mucu
layer
order
adher
colon
host
mucosa
includ
disrupt
balanc
mucu
eros
mucu
productionsecret
degrad
mucin
specif
proteinas
glycosidas
view
microorgan
evolv
one
sever
follow
strategi
fig
interact
mucin
ii
alter
mucin
synthesi
mucin
assembl
gel
iii
degrad
mucu
layer
iv
evas
mucin
altern
pathway
within
mucu
mucin
form
complex
network
act
trap
foreign
particul
compound
main
mechan
mucin
interact
foreign
bodi
follow
size
exclus
unspecif
polyval
hydrophil
hydrophob
interact
specif
bond
mucu
gel
network
heterogen
structur
wide
rang
pore
size
limit
particul
nm
travel
great
exampl
avoid
size
exclus
confer
mucu
mesh
obtain
enter
viru
fact
virion
use
intestin
mucosa
colon
host
regular
size
nm
ie
rotaviru
coronaviru
influenza
norwalk
fact
suggest
mucu
barrier
posit
select
viru
size
better
penetr
mesh
reach
effici
subjac
target
cell
howev
particul
nm
also
abl
diffus
mucu
circumst
relat
physicochem
properti
mucin
molecular
charg
densiti
anion
cation
group
numer
hydrophob
domain
distribut
surfac
fibr
result
adhes
interact
particl
mucu
achiev
electrostat
andor
hydrophob
interact
follow
mucin
filament
cover
glycosyl
residu
extent
show
acid
charact
due
presenc
sialic
sulphat
group
fig
thu
neg
charg
mucin
bind
high
avid
posit
charg
particul
counteract
anion
charact
number
enter
virion
display
extern
neutral
net
charg
therefor
neither
repel
wrap
mucu
larger
organ
like
bacteria
need
use
differ
strategi
exampl
helicobact
pylori
secret
glycosulphatas
releas
sulphat
group
mucin
avoid
electrostat
adsorpt
freeli
migrat
mucu
mucin
layer
also
contain
hydrophob
domain
along
fibr
structur
thu
continu
viru
exampl
natur
favour
enter
nake
viru
mean
nonenvelop
particl
contrast
block
hydrophob
bond
establish
mucin
hydrophob
domain
envelop
viral
particl
fig
fact
microbi
cell
suffer
limit
immobil
mucu
via
hydrophob
interact
complex
chemic
composit
mucin
facilit
specif
linkag
via
conform
interact
fig
fact
select
pressur
handl
pathogen
may
modul
ampl
varieti
mucin
glycosyl
pattern
exampl
found
bacteria
protozoa
adher
mucin
could
desir
strateg
step
avoid
natur
peristalt
flow
campylobact
jejuni
motil
bacterium
colon
intestin
vertebr
main
caus
human
acut
bacteri
gastroenter
evolutionari
adapt
mucosa
mucin
chemoattract
campylobact
bacterium
bind
avidli
specif
ligand
includ
lipopolysaccharid
lp
similarli
intestin
pathogen
protozoa
cryptosporidium
parvum
giardia
duodenali
express
surfac
lectin
adher
intestin
mucin
similar
way
h
pylori
attach
mucin
carbohydr
bloodgroup
antigenbind
sialic
acid
bind
adhesin
neutral
ph
howev
mucu
gel
releas
acid
gastric
milieu
interact
weak
allow
bacteria
detach
go
epithelium
similar
approach
describ
candida
salmonella
speci
specif
contact
candida
albican
mucin
establish
microorgan
releas
aspartyl
proteinas
degrad
surround
glycoprotein
move
deeper
mucu
layer
hand
salmonella
typhimurium
bind
specif
sialomucin
express
sialidas
degrad
mucin
liquefi
mucu
facilit
penetr
protect
layer
state
sign
import
mucin
host
defenc
secret
enhanc
respons
intestin
microb
order
solv
drawback
special
intestin
pathogen
capabl
express
virul
factor
either
alter
mucin
product
decreas
increas
modifi
mucin
assembl
outer
expos
bacteri
compon
exotoxin
flagellin
lp
lipoteicho
acid
known
modul
mucin
product
exampl
h
pylori
abl
decreas
mucin
biosynthesi
lp
cytosol
phospholipas
wherea
clostridium
difficil
use
socal
toxin
obtain
effect
pathogen
caus
mucin
hypersecret
order
produc
mucu
deplet
wellknown
vibrio
cholera
enterotoxin
increas
intracellular
level
adenosin
monophosph
activ
mucu
secret
mechan
intestin
goblet
cell
listeria
monocytogen
produc
exotoxin
listeriolysin
promot
synthesi
secret
mucin
purpos
colon
gastric
duodenum
mucosa
h
pylori
bacteria
releas
ureas
neutral
acid
ph
gener
ammonium
urea
increas
ph
trigger
transit
mucingel
mucinsolut
allow
bacteria
swim
mucu
addit
outer
membran
lp
also
inhibit
mucin
glycosyl
may
deleteri
effect
mucin
assembl
obviou
direct
mechan
freeli
move
mucu
barrier
degrad
thu
symbiot
intestin
bacteria
mucolyt
activ
glycosidas
proteas
purpos
get
monom
use
sourc
energi
turn
intestin
pathogen
use
similar
specif
enzym
open
small
breach
mucin
network
purpos
disassembl
oligomer
mucin
exampl
intestin
protozoa
eg
tritrichomona
giardia
lamblia
entamoeba
histolytica
may
express
sever
mucindegrad
enzym
thu
e
histolytica
secret
glycosidas
proteas
cleav
mucin
nonglycosyl
oligomer
domain
break
macromolecular
structur
reduc
mucu
viscos
bacteria
also
carri
specif
weapon
mucin
way
h
pylori
releas
glycosulphatas
disrupt
oligomer
structur
mucin
wherea
v
cholera
use
taga
proteas
purpos
similarli
salmonella
typhimurium
possess
sialidas
pseudomona
aeruginosa
enterotoxigen
escherichia
coli
strain
common
caus
diarrhoea
children
secret
specif
proteas
final
subcellular
world
also
find
interest
exampl
reoviru
also
releas
mucolyt
proteas
facilit
penetr
protect
mucu
barrier
enter
pathogen
capabl
reach
epitheli
cell
travel
follicleassoci
epithelium
fae
fae
overlay
gutassoci
lymphoid
tissu
galt
peyer
patch
pp
isol
lymphoid
follicl
integr
part
mucosalassoci
lymphoid
tissu
malt
intestin
order
mount
effici
immun
respons
lumin
antigen
microfold
cell
strateg
site
dome
epithelium
pp
cell
special
antigen
sampl
present
reduc
densiti
microvilli
addit
dome
epithelium
lack
goblet
cell
thu
make
special
sampl
area
mucu
barrier
minim
anoth
relat
special
featur
cell
present
deep
invagin
basolater
side
form
intraepitheli
pocket
contain
immunocompet
cell
spite
penetr
gut
mucosa
pathogen
believ
occur
mainli
cell
first
step
previou
invas
pathogen
interact
differ
pattern
recognit
receptor
prr
recogn
molecul
broadli
share
pathogen
distinguish
host
molecul
pathogenassoci
molecular
pattern
pamp
prr
includ
tolllik
receptor
tlr
nodlik
receptor
ctype
lectin
receptor
tlr
famili
particularli
express
cell
detect
exampl
lp
gram
neg
bacteria
mediat
lipoteicho
acid
gram
posit
bacteria
bacteri
flagellin
among
mani
other
pamp
enter
pathogen
exploit
receptor
invad
colon
host
receptor
local
mcell
use
microorgan
includ
specif
glycoconjug
complement
compon
receptor
thu
reoviru
specif
target
cell
interact
hemagglutinin
glycoconjug
termin
sialic
acid
residu
wherea
e
coli
typhimurium
use
fimbria
adhesin
fimh
specif
interact
also
express
cell
hand
outer
membran
protein
omph
yersinia
enterocolitica
recogn
shock
protein
brucella
abortu
interact
cellular
prion
protein
also
local
cell
sum
gut
cover
mucos
absorpt
epithelium
maintain
homoeostasi
restrict
transit
macromolecul
foreign
particl
howev
infect
occur
along
area
circumst
obviou
approach
would
use
whole
natur
recombin
attenu
pathogen
antigen
carrier
oral
vaccin
howev
mani
intrins
factor
preclud
use
revers
virul
immunogen
carrier
neutral
booster
immun
potenti
risk
associ
use
recombin
dna
possibl
safer
solut
oral
deliveri
antigen
allergen
would
use
microorganismlik
nanocarri
last
year
effort
direct
toward
enhanc
mucosalor
vaccin
deliveri
host
use
varieti
particul
deliveri
system
liposom
immunestimul
complex
iscom
nanoparticl
gener
point
view
nanocarri
offer
advantag
interest
oral
deliveri
antigen
allergen
vaccin
immunotherapi
purpos
respect
thu
encapsul
biomacromolecul
nanocarri
effect
protect
harsh
condit
gastrointestin
tract
minim
degrad
hydrolysi
digest
enzym
biolog
point
view
nanoparticl
may
also
act
adjuv
may
facilit
antigen
uptak
intern
galt
antigen
crosspresent
antigen
present
cell
apc
via
mhc
class
ii
pathway
unfortun
convent
nanocarri
interact
mucin
remain
immobil
mucu
layer
circumst
nanoparticl
clear
fast
mucu
remov
follow
advanc
movement
peristalt
forc
fig
thu
display
low
capabl
target
specif
site
within
gastrointestin
tract
eg
pp
mucos
dendrit
cell
dc
consequ
elicit
immun
respons
antigen
carrier
usual
high
necessari
offer
adequ
degre
protect
host
consequ
high
multipl
oral
dose
requir
order
overcom
drawback
render
nanoparticl
effici
adjuv
vaccin
one
possibl
outcom
coat
decor
compound
molecul
involv
strategi
develop
microorgan
reach
fae
fig
section
purpos
ligand
capabl
target
interact
either
epitheli
glycoconjug
specif
activ
pathogen
tlr
famili
mannos
receptor
mr
propos
interest
note
gener
pamp
also
immunopotenti
thu
may
improv
intens
qualiti
immun
respons
induc
antigenload
nanoparticl
parallel
mani
ligand
may
confer
mucusperm
properti
result
nanocarri
least
two
differ
mechan
former
hydrophil
ligand
yield
particul
surfac
less
liabl
develop
hydrophob
interact
mucin
fibr
compon
mucu
layer
later
ligand
eg
type
bacteri
lp
flagellin
may
also
inhibit
product
mucu
glycoprotein
see
section
biomimet
approach
differ
ligand
propos
includ
use
flagellin
lp
deriv
apart
capabl
modul
product
mucin
specif
tlr
ligand
also
import
effect
immunomodul
adjuv
fact
compound
alert
apc
presenc
pathogen
materi
thu
facilit
induct
adequ
immun
respons
lipopolysaccharid
global
recogn
one
main
pamp
macromolecul
locat
outer
membran
gram
neg
bacteria
show
capabl
activ
apc
receptor
membran
potenti
cellular
respons
howev
lp
also
known
endotoxin
show
potent
biolog
activ
deleteri
side
effect
effect
relat
presenc
lipid
nonetheless
natur
lp
differ
bacteria
may
exhibit
differ
biolog
properti
includ
capabl
tlr
agonist
effect
pyrogen
materi
hand
nontox
altern
develop
includ
synthesi
modifi
product
structur
relat
lp
devoid
toxic
way
monophosphoryl
lipid
mpl
deriv
lp
salmonella
enterica
serovar
minnesota
first
tlr
ligand
biolog
adjuv
approv
human
use
safeti
effect
moreov
test
numer
human
trial
differ
infecti
diseas
hepat
b
malaria
herp
simplex
viru
allergen
immunotherapi
regard
use
improv
immun
respons
antigen
encapsul
nanocarri
mpl
incorpor
extern
bilay
liposom
contain
glucosyltransferas
antigen
streptococcu
mutan
administ
oral
liposom
induc
high
level
salivari
plasma
vagin
iga
demonstr
capabl
combin
nanocarri
lp
deriv
induc
strong
mucos
immun
respons
similar
way
sarti
cowork
use
plga
nanoparticl
associ
mpl
demonstr
import
improv
immun
respons
ovalbumin
ova
lp
deriv
present
interestingli
result
obtain
administr
one
singl
oral
dose
anoth
studi
plgalipid
nanocarri
function
surfac
mpl
mcell
specif
lectin
stimul
effect
mucos
serum
antibodi
model
antigen
mice
presenc
mpl
appear
key
factor
elicit
immun
respons
nanoparticl
capabl
penetr
mucu
layer
reach
inner
mucu
layer
iml
resid
would
longer
time
sinc
iml
renew
slower
thu
facilit
greater
dose
particl
cargo
releas
nearbi
underlay
cell
b
particl
even
reach
glycocalyx
cellular
membran
microorgan
c
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
nowaday
new
gener
agonist
develop
glucopyranosyl
lipid
adjuv
aminoalkyl
glucosaminid
howev
best
knowledg
research
use
oral
vaccin
deliveri
system
limit
anoth
approach
take
advantag
adjuv
potenti
lp
use
molecul
low
toxic
context
propos
use
rough
lp
brucella
ovi
show
low
endotox
lp
use
decor
poli
anhydrid
nanoparticl
carri
ova
model
allergen
oral
administ
mice
lpscoat
nanoparticl
capabl
reach
larg
extent
surfac
intestin
epithelium
includ
pp
import
capabl
reach
epithelium
line
high
degre
protect
offer
lpsnanoparticl
close
anaphylact
shock
ovasensit
anim
similar
approach
use
lolium
perenn
protein
extract
coat
poli
anhydrid
nanoparticl
lp
b
ovi
shift
immun
respons
observ
nake
nanoparticl
profil
sensit
murin
model
allergen
cellular
respons
induc
lpscoat
nanoparticl
identifi
key
aspect
respons
efficaci
nanoparticl
fact
challeng
experi
sensit
mice
lpsnanocarri
decreas
level
mous
mast
cell
proteas
sever
anaphylact
symptom
increas
surviv
rate
anim
compar
control
flagellin
monomer
protein
conform
bacteri
flagellum
key
virul
factor
pathogen
provid
motil
increas
adhes
exampl
flagel
bacteria
includ
h
pylori
vibrio
salmonella
pseudomona
speci
flagellin
extens
investig
pamp
sinc
bind
furthermor
flagellin
induc
matur
intestin
dc
activ
cell
vivo
promot
develop
mix
effector
th
cell
respons
mucos
adjuv
flagellin
almost
potent
v
cholera
e
coli
heatlabil
toxin
much
safer
two
compound
order
evalu
advantag
offer
combin
pamp
nanocarri
antigen
oral
deliveri
system
flagellin
flagella
salmonella
enteritidi
use
function
poli
anhydrid
nanoparticl
administ
oral
nanocarri
display
import
capabl
reach
surfac
epithelium
mainli
ileum
laboratori
anim
interestingli
distribut
profil
nanoparticl
within
gut
correl
well
describ
colon
profil
salmonella
enteritidi
includ
broad
concentr
pp
use
ovalbumin
model
antigen
flagellinco
nanoparticl
elicit
strong
balanc
secret
specif
antibodi
furthermor
nanoparticl
abl
induc
much
strong
mucos
iga
respons
nake
nanoparticl
flagellin
relat
compound
also
use
decor
type
nanocarri
includ
liposom
viru
like
particl
polypropylen
sulphid
nanoparticl
recent
flagellinfunction
calcium
phosphat
nanoparticl
induc
significantli
higher
immunostimulatori
effect
mainli
relat
high
level
proinflammatori
cytokin
control
glycoconjug
enrich
mannos
residu
promot
interact
number
microorgan
eg
c
albican
l
monocytogen
leishmania
donovani
hiv
enterobacteriacea
bifidobacterium
differ
tissu
substrat
includ
lymphoid
nonlymphoid
cell
differ
mucos
surfac
bind
mediat
high
affin
either
mannos
glycoconjug
end
mannos
socal
mannosebind
lectin
mr
immun
cell
ie
dc
macrophag
mr
mediat
endocytosi
function
antigen
captur
receptor
involv
antigen
captur
present
context
mannosyl
nanocarri
obtain
decor
particul
mannos
deriv
consid
promis
nonliv
vector
mucos
vaccin
thu
mannosyl
niosom
load
tetanu
toxoid
tt
evalu
oral
vaccin
tetanu
coat
vesicl
linear
polym
mannos
opalmitoyl
mannan
improv
stabil
presenc
bile
salt
digest
enzym
furthermor
function
nanocarri
capabl
target
pp
elicit
import
humor
cellular
respons
measur
sera
level
similarli
iga
level
mucos
secret
also
high
tt
similar
work
mannosyl
niosom
evalu
oral
vaccin
carrier
plasmid
design
express
hepat
b
viru
protein
anim
immun
mannosyl
niosom
offer
adequ
antibodi
level
get
seroprotect
hepat
b
viru
infect
mannosyl
liposom
also
propos
oral
vaccin
thu
liposom
function
mannos
deriv
mannosepegcholesterol
conjug
induc
potent
immun
respons
model
antigen
bovin
serum
albumin
bsa
oral
administ
immun
respons
character
high
level
sera
igg
siga
differ
mucos
secret
recent
studi
mannosamineco
polymer
nanoparticl
use
load
hot
salin
extract
b
ovi
hs
vaccin
mice
singl
oral
dose
nanocarri
offer
import
protect
experiment
infect
bacteria
fact
degre
protect
measur
reduct
b
ovi
cfu
spleen
obtain
mannosyl
nanoparticl
higher
nake
nanoparticl
higher
control
howev
anim
conjunctiv
vaccin
mannosyl
nanoparticl
degre
protect
challeng
highest
even
observ
commerci
vaccin
intramuscularli
administ
degre
protect
relat
fact
mannosyl
nanoparticl
instil
eye
distribut
via
nasolacrim
duct
nose
gastrointestin
tract
fact
h
instil
nanoparticl
visual
cornea
nose
intestin
mucosa
includ
pp
import
highlight
area
nanoparticl
encount
apc
thu
induc
potenti
immun
respons
glucomannan
water
solubl
polysaccharid
compris
glucos
mannos
also
propos
decor
differ
nanocarri
includ
bilosom
chitosan
nanoparticl
case
use
tt
demonstr
function
nanocarri
elicit
significantli
higher
system
mucos
immun
respons
control
addit
ttload
glucomannan
nanocarri
also
induc
cell
mediat
immun
respons
interpherongamma
induc
convent
vaccin
base
alum
intramuscularli
inject
intestin
epitheli
cell
possess
cell
surfac
glycocalyx
compos
membran
anchor
glycoconjug
may
therefor
possibl
exploit
surfac
expos
carbohydr
residu
target
lectinmedi
deliveri
specif
region
celltyp
within
gastrointestin
tract
sever
studi
reveal
mani
speci
mani
malt
site
cell
surfac
glycocalyx
differ
carbohydr
composit
enterocyt
one
first
attempt
evalu
capabl
lectin
specif
target
mcell
coat
liposom
nanoparticl
ulex
europaeu
agglutinin
lectin
specif
alfucos
residu
use
model
antigen
eg
ova
bsa
coat
particul
capabl
reach
target
cell
pp
induc
system
humor
respons
significantli
higher
elicit
nontarget
antigen
recent
malik
cowork
demonstr
coat
bsaload
chitosan
nanoparticl
conjug
algin
produc
nanocarri
capabl
induc
superior
system
respons
laboratori
anim
along
mucos
immun
significantli
higher
induc
convent
aluminiumbas
vaccin
immun
effect
would
consequ
rapid
endocytosi
process
nanocarri
adhes
cell
would
facilit
captur
mucos
dc
immunocompet
cell
subepitheli
dome
intestin
pp
tissu
lectin
demonstr
import
abil
target
enhanc
pp
uptak
associ
nanocarri
follow
wheat
germ
agglutinin
peanut
agglutinin
asparagu
pea
lectin
aleuria
aurantia
lectin
tabl
summar
exampl
relat
function
nanocarri
lectin
oral
vaccin
purpos
oral
administr
antigen
allergen
vaccin
immunotherapi
attract
patient
complianc
needl
free
system
logist
coldchain
requir
support
immunolog
foundat
fact
gut
mucos
surfac
major
portal
entri
major
known
pathogen
allergen
act
mucosa
first
line
immun
respons
galt
nevertheless
arriv
antigen
allergen
galt
face
number
barrier
first
compound
highli
sensit
harsh
condit
gut
gener
rapidli
degrad
extrem
ph
condit
andor
digest
enzym
second
mucu
layer
constitut
formid
hurdl
greatli
hamper
encount
interact
antigen
andor
allergen
antigen
present
cell
third
antigen
elicit
strong
longlast
adequ
protect
immun
respons
order
solv
barrier
differ
strategi
propos
includ
use
nanocarri
nanocarri
eg
polymer
nanoparticl
liposom
iscom
good
option
protect
cargo
earli
degrad
within
hostil
environment
condit
eg
acid
ph
enzym
howev
nanocarri
oral
administ
interact
mucin
fibr
import
fraction
given
dose
remain
trap
protect
mucu
layer
consequ
nanocarri
rapidli
elimin
physiolog
mucu
turnov
gut
peristalt
one
possibl
solut
minim
problem
would
decor
nanocarri
ligand
capabl
mimick
abil
microorgan
cross
protect
mucu
layer
reach
epithelium
basic
bacteria
viru
use
two
type
mucusperm
strategi
first
set
includ
particular
physicochem
properti
minim
interact
compon
mucu
layer
eg
size
surfac
charg
hydrophil
charact
second
set
encompass
biolog
solut
releas
proteolyticglycosid
enzym
use
propel
system
presenc
compound
capabl
specif
interact
receptor
host
howev
interest
note
gener
microorgan
use
simpl
uniqu
strategi
combin
cross
mucu
layer
point
view
associ
nanocarri
compound
particular
specif
certain
receptor
local
galt
tlr
mr
particular
glycoconjug
good
option
induc
adequ
immun
respons
purpos
ligand
eg
glycoconjug
flagellin
lp
lectin
coval
bound
surfac
nanocarri
load
biolog
activ
molecul
import
advantag
obtain
combin
first
hydrophil
natur
neutral
charact
ligand
attach
surfac
nanocarri
would
decreas
electrostat
hydrophob
interact
mucin
increas
possibl
nanocarri
reach
epitheli
surfac
deliv
cargo
case
flagellin
lp
due
capabl
decreas
synthesi
mucin
hypothes
could
also
decreas
viscos
mucu
layer
favour
arriv
nanocarri
epithelium
second
capabl
ligand
specif
interact
prr
cell
surfac
eg
tlr
mr
glycoconjug
would
improv
possibl
result
nanocarri
reach
galt
includ
cell
pp
thu
target
properti
would
line
colon
pattern
observ
microorgan
colon
process
host
gut
mucosa
facilit
antigen
present
activ
immun
system
last
least
immunoadjuv
properti
ligand
would
boost
protect
immun
respons
anoth
interest
altern
biomimet
approach
would
incorpor
proteas
glycosidas
specif
mucin
pampscoat
devic
combin
increas
fraction
nanocarri
capabl
reach
surfac
epithelium
thu
efficaci
antigenallergen
deliveri
system
howev
bind
second
compound
surfac
nanocarri
may
neg
affect
target
properti
inde
efficaci
tabl
exampl
oral
immun
use
lectinfunction
nanocarri
lectincoupl
microspher
display
affin
mcell
show
preferenti
bind
pp
ulex
europaeu
agglutinin
bsa
liposom
liposom
induc
simultan
system
mucos
immun
respons
mice
aleuria
aurantia
lectin
birch
pollen
protein
plga
microspher
allerg
mice
treat
lectinfunction
microparticl
induc
import
level
ifnc
research
necessari
order
implement
adequ
methodolog
decor
nanocarri
differ
compound
without
loss
efficaci
mucos
deliveri
system
well
select
adequ
ligand
boost
appropri
immun
pathogen
allergi
author
certifi
conflict
interest
financi
organ
regard
materi
discuss
manuscript
